LONDON -- The shares of�Carpetright� (LSE: CPR ) rose 2.4% to 265 pence in early afternoon trading yesterday after the FTSE 250 mid cap revealed like-for-like U.K. sales had jumped 5.6%.
Carpetright, the biggest seller of carpets and floor coverings in Britain, met market expectations by confirming gross margins were likely to improve by 0.2% this year.
The company's performance in the rest of Europe was less impressive, however, with total sales declining 10.2%, mostly due to "deteriorating economic conditions" in the Netherlands.
After suffering a disastrous blow to margins following the housing crisis, Carpetright said it would continue its plans to refurbish its U.K. stores, increase its product range, and focus on digital media marketing.
Chief executive Darren Shapland commented:
Excluding the expected contraction in sales from the wholesale business, our core U.K. retail business would have reported like-for-like sales growth of 6.7% for the period. Whilst the recent cold spring weather has been positive to our sales, we believe this performance reflects the continued success of our program of self-help initiatives.
Hot Cheap Companies To Watch For 2015: SBT Bancorp Inc (SBTB)
SBT Bancorp, Inc., incorporated on February 17, 2006, is the holding company for The Simsbury Bank & Trust Company, Inc. (the Bank). The Bank provides a variety of banking and investment services. The Bank has branch offices in the towns of Granby, Avon, and Bloomfield, Connecticut. The Bank also maintains a mortgage center in Canton, Connecticut. Services to the Bank�� customers are also provided through SBT Online Internet banking. The Bank's customer base consists primarily of individual consumers and small businesses in north central Connecticut. The Bank has in excess of 21,000 deposit accounts. In January 2011, the Bank formed Simsbury Bank Passive Investment Company, a subsidiary of Passive Investment Company (PIC).
During the year ended December 31, 2011, the Bank had seven automated teller machines (ATMs); two are located at each of its main office and its Bloomfield office, and one at each of the other branch/business offices. The Bank offers a range of commercial banking services to residents and businesses in its primary and secondary markets through a variety of commercial loans and residential mortgage programs, as well as home equity lines and loans, Federal Deposit Insurance Corporation (FDIC)-insured checking, savings, and individual retirement accounts (IRA), 401K rollover accounts, as well as safe deposit and other customary non-deposit banking services. The Bank offers investment products to customers through SBT Investment Services, Inc., a wholly owned subsidiary of the Bank, and through its affiliation with the securities broker/dealer LPL Financial Corporation.
Lending Activities
The Bank�� commercial loans are made for the purpose of providing working capital, financing the purchase of equipment, or for other business purposes. Such loans include loans with maturities ranging from thirty days to two years and term loans, which are loans with maturities normally ranging from 1 to 10 years. Short-term business loans are generally inten! ded to finance current transactions and typically provide for periodic principal payments, with interest payable monthly. Term loans normally provide for fixed or floating interest rates, with monthly payments of both principal and interest. The Bank�� construction loans are primarily interim loans made to finance the construction of commercial and single-family residential property. These loans are typically short-term. The Bank occasionally will make loans for speculative housing construction or for acquisition and development of raw land. Consumer loans are made for the purpose of financing automobiles, various types of consumer goods, and other personal purposes.
Investment Activities
As of December 31, 2011, the Bank�� investment portfolio consisted of the United States Government and agency securities, mortgage-backed securities, corporate bonds, municipal securities, and money market mutual funds. During 2011, proceeds from sales of available-for-sale securities amounted to $8,274,474.
Sources of Funds
Deposits are the Bank�� primary source of funds. At December 31, 2011, the Bank had a deposit mix of 43% checking, 34% savings, and 23% certificates of deposit. Thirty percent of the total deposits of $344.8 million were noninterest bearing at December 31, 2011. The Bank had brokered deposits of $9,017,198 as of December 31, 2011.
The Company competes with Bank of America, Webster Bank, People�� Bank, Windsor Federal Savings And Loan Association and Wells Fargo Bank.
Advisors' Opinion:- [By CRWE]
Today, SBTB remains (0.00%) +0.000 at $28.20 thus far (ref. google finance Delayed: 3:47PM EDT July 30, 2013).
SBT Bancorp, Inc., previously reported net income of $401,000 or $0.43 per diluted share for the second quarter of 2013, compared to $453,000 or $0.49 per diluted share for the second quarter of 2012.
For the six months ended June 30, 2013, net income amounted to $918,000, or $0.99 per diluted share. This compares to net income of $934,000 or $0.96 per diluted share for the six months ended June 30, 2012. Total assets on June 30, 2013 were $382 million compared to $340 million on June 30, 2012. 12
Top 5 Mid Cap Companies To Buy Right Now: Texas Rare Earth Resources Corp (TRER.PK)
Texas Rare Earth Resources Corp., formerly Standard Silver Corporation, incorporated on July 29, 1970. a mining company engaged in the business of the acquisition and development of mineral properties. As of August 31, 2012, it held a nineteen year lease to explore and develop a 950 acre rare earth uranium-beryllium prospect located in Hudspeth County, Texas known as Round Top and prospecting permits covering an adjacent 9,345 acres.
The Company�� principal focus will be on developing a metallurgical process to concentrate or otherwise extract the metals from the Round Top rhyolite. In addition to the Round Top Project, the Company also own title to 12 unpatented mining claims, the Macho group, comprising 240 acres covering the Old Dude Mine, located in Sierra County, New Mexico. Another 18 unpatented mining claims and fractional claims, the HA group, consisting 274 acres cover an andesite hosted vein system similar to and some 10 miles to the southwest of the Macho District.
Advisors' Opinion:- [By Jake Mitchell]
As a speculative play on the industry, I came across Texas Rare Earth Resources (TRER.PK), which is principally focused on its 950 acre Round Top project. A Preliminary Economic Assessment by an independent third party found that there are an estimated over 1 billion metric tonnes of resources containing over 1 billion pounds of rare earth elements. A revised PEA, which was originally projected to have a capital cost of $2.1 billion is now estimated to be between $150 million to $350 million. A key concern in the exploration of these mines is how expensive it is to ultimately extract the rare earths from the ground. If Texas Rare Earth is able to show evidence that cost has been significantly reduced it will be the target of interested parties globally.
Top 5 Mid Cap Companies To Buy Right Now: Becton Dickinson and Company(BDX)
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company?s BD Medical segment produces medical devices that are used in various healthcare settings. This segment?s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes, pen needles, and other drugs to treat diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Diagnostics segment provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment?s products consist of integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. The company?s BD Biosciences segment produces research and clinical tools that facilitate the study of cells and their components. This segment?s products comprise fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It markets its products through independent distribution channels and independent sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Advisors' Opinion:- [By Victor Selva]
The company has a very attractive current ratio of 33.03% which is higher than its comps: Becton Dickinson & Co (BDX), Cardinal Health Inc (CAH), Cooper Companies (COO) and Luxottica Group S.p.A. (LUX).
- [By Ben Levisohn]
Becton Dickinson (BDX) has gained 1.2% to $101.97 this morning after�Piper Jaffray�raised the stock to Overweight from Neutral. Analysts�William Quirk and�David Clair�explain why they’re optimistic about the medical technology company:
Associated PressObservations from multiple diagnostic conferences all suggest significant interest in�microbiology investment. This interest spans track systems (Kiestra), new identification�technologies (Maldi/BioTyper) and Molecular (gram +/- assays). When considering�AST (antimicrobial susceptibility testing) recall from Siemens, we believe BD’s�microbiology business is poised to accelerate its performance over the next several years.�Combined with a delayed JNJ/Ypsomed pen needle launch and incremental European�safety adoption, we believe numbers for BD will continue to climb…
They also raised their price target to $117 from $91.
While Becton has gained today,�Johnson & Johnson�(JNJ) has dropped 0.6% to $88.50,�Medtronic�(MDT) has fallen 1%to $53.43,�Boston Scientific�(BSX) has declined 0.9% to $11.79 and Edwards Lifesciences (EW) is off 1.2% at $70.90.
- [By Geoff Gannon]
Someone who reads my articles sent me this question: My��uestion has to do with the type of investments you tend to put your energy toward. Evaluating a net-net is a whole lot different than evaluating a company that has a competitive advantage and trades at much higher multiples. To me, the net-net evaluation process is a whole lot more straightforward, as there are fewer intangibles (if any) and less prediction about the future involved. I don't have to worry about whether GTSI (GTSI) has any competitive advantage ��I know it doesn't. Then again, I look at a company like Becton Dickenson (BDX) and I see a highly predictable company with a decent moat selling at a reasonable price. I can look at BDX and figure I might earn 10-15% annually over a long time frame. That's really different from thinking about investing in a net-net where I can see how it's 30-50% undervalued now, but it's not something I'm going to hold onto for decades. It's more of a matter of waiting for that one-time "pop" that will happen sometime in the next 1-5 years. How do you decide where to put your energy?
- [By Eric Volkman]
Becton, Dickinson & Co.� (NYSE: BDX ) shareholders will receive their next dividend at the end of September. The company has declared its latest common stock payout, which is to be $0.495 per share paid on September 30 to shareholders of record as of September 9. That amount matches each of the firm's previous three distributions, the most recent of which was paid at the end of last month. Prior to that, Becton Dickinson handed out $0.45 per share.
Top 5 Mid Cap Companies To Buy Right Now: Guided Therapeutics Inc (GTHP)
Guided Therapeutics, Inc., incorporated on October 27, 1992, is a medical technology company focused on developing medical devices. The Company�� primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. Its technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix.
The Company's product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions. The product is expected to incorporate a single-use, disposable calibration and alignment component.
The Company competes with Qiagen, MediSpectra, Inc., Merck & Co., Inc., and GlaxoSmithKline PLC.
Advisors' Opinion:- [By CRWE]
Today, GTHP remains (0.00%) +0.000 at $.710 with 44,700 shares in play thus far (ref. google finance Delayed: 11:42AM EDT August 21, 2013).
Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.
Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.
No comments:
Post a Comment